Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second Line Treatment of Stage IIIB or IV NSCLC
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Docetaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 23 Jun 2017 Status changed from completed to discontinued.
- 21 Sep 2016 Status changed from active, no longer recruiting to completed.
- 02 May 2016 New trial record